The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients (pts): An exploratory retrospective analysis.
Luigi Coltelli
No relevant relationships to disclose
Andrea Fontana
No relevant relationships to disclose
Guido Bocci
No relevant relationships to disclose
Andrea Camerini
No relevant relationships to disclose
Antonella Ferro
No relevant relationships to disclose
Marina Elena Cazzaniga
No relevant relationships to disclose
Virginia Casadei
No relevant relationships to disclose
Ilaria Pazzagli
No relevant relationships to disclose
Lorenzo Marcucci
No relevant relationships to disclose
Giacomo Allegrini
No relevant relationships to disclose
Sara Lucchesi
No relevant relationships to disclose
Eleonora Bona
No relevant relationships to disclose
Marco Scalese
No relevant relationships to disclose
Paola Orlandi
No relevant relationships to disclose
Federica Villa
No relevant relationships to disclose
Silvano Morini
No relevant relationships to disclose
Domenico Amoroso
No relevant relationships to disclose
Giada Arrighi
No relevant relationships to disclose
Mario Filidei
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose